HFD decreases intermediate-term memory. by Tong Yue (6033305)

“…(C) Food intake was not significantly different between ND- and HFD-fed flies during the 1 hour. …”

Multivariate regression analysis to explain the decrease in visibility and palpability. by Miharu Matsumoto (21304390)

Table_1_FMT intervention decreases urine 5-HIAA levels: a randomized double-blind controlled study.DOCX by Lihong Wang (14991)

“…However, in the placebo group, GSRS, CARS, and SRS scores showed no significant changes, while ABC scores decreased from 72 to 58.75 (p = 0.034). …”

Metabolites with decreasing levels during the development. by Martin Sládek (130663)

“…<p>Temporal profiles of polar metabolites and lipids with SCN levels significantly decreasing from E19 to P28. Rhythmicity was determined by eJTK; full or dashed lines depict the profiles that either did or did not pass the significance threshold (FDR-adjusted <i>P</i> < 0.05), respectively.…”

Tetrandrine decreases Mtb antigen presentation. by Elham Karamooz (2584474)

Details of significantly differentially abundant metabolites (<i>PPP1CC</i>-SSKO vs control). by Jiahong Sun (6497603)

The level of miRNA 221 in the myocardium of MIRI mice was decreased. by Hongyu Li (1332669)

Subjects:

Phosphorylation as an Effective Tool to Improve Stability and Reduce Toxicity of Antimicrobial Peptides by Zufang Ba (11036420)

“…Among them, W₃BipY₈-P stood out as the most promising peptide, exhibiting similar antibacterial activity as its unphosphorylated analog W₃BipY₈ but with significantly reduced hemolytic activity (19-fold decrease), cytotoxicity (3.3-fold decrease), and an extended serum half-life 6.3 times longer than W₃BipY₈. …”

CBCHCV rawdata. This file contains the raw dataset used in the analysis of decreased levels of inflammatory markers in patients with hepatitis C virus (HCV) infection. The dataset... by Lu Han (151620)

Subjects:

Significant Decrease in Vessel Count of Trade Vessels in (a) Bosporus Strait and (b) Bab el-Mandeb Strait. by Cherryl Chico (20978829)

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Study selection criteria. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

PICOS criteria for the SLR. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects: